BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 27289491)

  • 1. Evidence Supporting a Lymphatic Endothelium Origin for Angiomyolipoma, a TSC2(-) Tumor Related to Lymphangioleiomyomatosis.
    Yue M; Pacheco G; Cheng T; Li J; Wang Y; Henske EP; Schuger L
    Am J Pathol; 2016 Jul; 186(7):1825-1836. PubMed ID: 27289491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of gene expression array in TSC2-deficient AML cells reveals IRF7 as a pivotal factor in the Rheb/mTOR pathway.
    Makovski V; Jacob-Hirsch J; Gefen-Dor C; Shai B; Ehrlich M; Rechavi G; Kloog Y
    Cell Death Dis; 2014 Dec; 5(12):e1557. PubMed ID: 25476905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
    Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB
    J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mammalian target of rapamycin signaling and autophagy: roles in lymphangioleiomyomatosis therapy.
    Yu J; Parkhitko AA; Henske EP
    Proc Am Thorac Soc; 2010 Feb; 7(1):48-53. PubMed ID: 20160148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole Exome Sequencing Identifies TSC1/TSC2 Biallelic Loss as the Primary and Sufficient Driver Event for Renal Angiomyolipoma Development.
    Giannikou K; Malinowska IA; Pugh TJ; Yan R; Tseng YY; Oh C; Kim J; Tyburczy ME; Chekaluk Y; Liu Y; Alesi N; Finlay GA; Wu CL; Signoretti S; Meyerson M; Getz G; Boehm JS; Henske EP; Kwiatkowski DJ
    PLoS Genet; 2016 Aug; 12(8):e1006242. PubMed ID: 27494029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statins in lymphangioleiomyomatosis. Simvastatin and atorvastatin induce differential effects on tuberous sclerosis complex 2-null cell growth and signaling.
    Atochina-Vasserman EN; Goncharov DA; Volgina AV; Milavec M; James ML; Krymskaya VP
    Am J Respir Cell Mol Biol; 2013 Nov; 49(5):704-9. PubMed ID: 23947572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.
    Li C; Zhang E; Sun Y; Lee PS; Zhan Y; Guo Y; Osorio JC; Rosas IO; Xu KF; Kwiatkowski DJ; Yu JJ
    PLoS One; 2014; 9(10):e104809. PubMed ID: 25347447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of cells cultured from chylous effusion from a patient with sporadic lymphangioleiomyomatosis.
    Grzegorek I; Zuba-Surma E; Chabowski M; Janczak D; Szuba A; Dziegiel P
    Anticancer Res; 2015 Jun; 35(6):3341-51. PubMed ID: 26026094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon beta augments tuberous sclerosis complex 2 (TSC2)-dependent inhibition of TSC2-null ELT3 and human lymphangioleiomyomatosis-derived cell proliferation.
    Goncharova EA; Goncharov DA; Chisolm A; Spaits MS; Lim PN; Cesarone G; Khavin I; Tliba O; Amrani Y; Panettieri RA; Krymskaya VP
    Mol Pharmacol; 2008 Mar; 73(3):778-88. PubMed ID: 18094073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapamycin-insensitive up-regulation of MMP2 and other genes in tuberous sclerosis complex 2-deficient lymphangioleiomyomatosis-like cells.
    Lee PS; Tsang SW; Moses MA; Trayes-Gibson Z; Hsiao LL; Jensen R; Squillace R; Kwiatkowski DJ
    Am J Respir Cell Mol Biol; 2010 Feb; 42(2):227-34. PubMed ID: 19395678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The methylation of the TSC2 promoter underlies the abnormal growth of TSC2 angiomyolipoma-derived smooth muscle cells.
    Lesma E; Sirchia SM; Ancona S; Carelli S; Bosari S; Ghelma F; Montanari E; Di Giulio AM; Gorio A
    Am J Pathol; 2009 Jun; 174(6):2150-9. PubMed ID: 19443708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tuberin regulates E-cadherin localization: implications in epithelial-mesenchymal transition.
    Barnes EA; Kenerson HL; Jiang X; Yeung RS
    Am J Pathol; 2010 Oct; 177(4):1765-78. PubMed ID: 20813961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tuberous sclerosis complex 2 loss increases lysophosphatidylcholine synthesis in lymphangioleiomyomatosis.
    Priolo C; Ricoult SJ; Khabibullin D; Filippakis H; Yu J; Manning BD; Clish C; Henske EP
    Am J Respir Cell Mol Biol; 2015 Jul; 53(1):33-41. PubMed ID: 25780943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the CXCR4/CXCL12 axis in lymphangioleiomyomatosis and angiomyolipoma.
    Clements D; Markwick LJ; Puri N; Johnson SR
    J Immunol; 2010 Aug; 185(3):1812-21. PubMed ID: 20585037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis.
    Smolarek TA; Wessner LL; McCormack FX; Mylet JC; Menon AG; Henske EP
    Am J Hum Genet; 1998 Apr; 62(4):810-5. PubMed ID: 9529362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abnormal growth of smooth muscle-like cells in lymphangioleiomyomatosis: Role for tumor suppressor TSC2.
    Goncharova EA; Goncharov DA; Spaits M; Noonan DJ; Talovskaya E; Eszterhas A; Krymskaya VP
    Am J Respir Cell Mol Biol; 2006 May; 34(5):561-72. PubMed ID: 16424383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a lymphangioleiomyomatosis model by endonasal administration of human TSC2-/- smooth muscle cells in mice.
    Lesma E; Eloisa C; Isaia E; Grande V; Ancona S; Orpianesi E; Di Giulio AM; Gorio A
    Am J Pathol; 2012 Sep; 181(3):947-60. PubMed ID: 22770663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-EGFR antibody efficiently and specifically inhibits human TSC2-/- smooth muscle cell proliferation. Possible treatment options for TSC and LAM.
    Lesma E; Grande V; Ancona S; Carelli S; Di Giulio AM; Gorio A
    PLoS One; 2008; 3(10):e3558. PubMed ID: 18958173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TSC2 epigenetic defect in primary LAM cells. Evidence of an anchorage-independent survival.
    Lesma E; Ancona S; Sirchia SM; Orpianesi E; Grande V; Colapietro P; Chiaramonte E; Di Giulio AM; Gorio A
    J Cell Mol Med; 2014 May; 18(5):766-79. PubMed ID: 24606538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of beta-agonists on LAM progression and treatment.
    Le K; Steagall WK; Stylianou M; Pacheco-Rodriguez G; Darling TN; Vaughan M; Moss J
    Proc Natl Acad Sci U S A; 2018 Jan; 115(5):E944-E953. PubMed ID: 29339522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.